A dose- and time-dependent effect of oxythiamine on cell growth inhibition in non-small cell lung cancer.
Apoptosis
Cell cycle
NSCLC
Oxythiamine
Thiamine-dependent enzymes
Journal
Cognitive neurodynamics
ISSN: 1871-4080
Titre abrégé: Cogn Neurodyn
Pays: Netherlands
ID NLM: 101306907
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
12
07
2021
revised:
05
09
2021
accepted:
16
09
2021
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
ppublish
Résumé
The high mortality rate of non-small-cell lung cancer (NSCLC) is mostly due to the high risk of recurrence. A comprehensive understanding of proliferation mechanisms of NSCLC would remarkably contribute to blocking up the invasion and metastasis of tumor cells. In our previous study, the remarkable decreased activity of Thiamine-dependent enzymes (TDEs), involving in intermediary metabolism responsible for energy production of tumor, was found under conditions of thiamine deficiency in vivo. To explore the effect of Oxythiamine (OT), a TDEs antimetabolite, on cell growth, we co-cultured A549 cells with OT in vitro at various doses (0.1, 1, 10 and 100 μM) and time periods (6, 12, 24 and 48 h) and subsequent cell proliferation and apoptosis assays were performed respectively. Our findings demonstrated that A549 cells proliferation was significantly downregulated by OT treatment in a progressively dose as well as time dependent manner. Inhibition of TDEs resulted in antagonism of lung cancer growth by inducing cells to cease the cycle as well as apoptotic cell death. We concluded a critical role of OT, a TDEs antagonistic compound, indicating the potential target of its practical use.
Identifiants
pubmed: 35603057
doi: 10.1007/s11571-021-09725-7
pii: 9725
pmc: PMC9120279
doi:
Types de publication
Journal Article
Langues
eng
Pagination
633-641Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Conflict of interestNo conflict of interest needs to declare.
Références
Clin Transl Oncol. 2016 Feb;18(2):196-205
pubmed: 26179749
Exp Hematol Oncol. 2013 Jul 27;2:18
pubmed: 23890079
Ann Neurol. 2017 Sep;82(3):317-330
pubmed: 28856750
Cell Metab. 2019 Nov 5;30(5):903-916.e7
pubmed: 31523006
J Proteome Res. 2010 Feb 5;9(2):980-9
pubmed: 20035555
Eur Respir J. 2011 Jun;37(6):1453-65
pubmed: 20884743
Bioorg Med Chem Lett. 2008 Mar 15;18(6):2206-10
pubmed: 18267359
J Gastroenterol Hepatol. 2000 Jul;15(7):706-17
pubmed: 10937674
Cancer Res. 2011 Feb 1;71(3):1156-66
pubmed: 21266352
Am J Pathol. 2011 Sep;179(3):1405-14
pubmed: 21763680
Int J Oncol. 2013 Jan;42(1):44-54
pubmed: 23135628
Cancer Res. 2010 Aug 1;70(15):6368-76
pubmed: 20647326
Nat Commun. 2017 Jan 10;8:13892
pubmed: 28071751
Int J Cancer. 2006 Dec 15;119(12):2733-41
pubmed: 17019714
Genet Mol Res. 2015 Sep 21;14(3):11043-51
pubmed: 26400334
PLoS Biol. 2017 Jun 26;15(6):e2002711
pubmed: 28650960
Clin Exp Metastasis. 2010 May;27(5):341-9
pubmed: 20449639
Cancer Metab. 2013 Jul 24;1(1):16
pubmed: 24280319
Nutrients. 2020 Nov 04;12(11):
pubmed: 33158037
N Engl J Med. 2020 Aug 13;383(7):640-649
pubmed: 32786189
N Engl J Med. 2017 Aug 31;377(9):849-861
pubmed: 28854088
Biosens Bioelectron. 2017 Jan 15;87:850-857
pubmed: 27657847
Mol Cell Endocrinol. 2020 Jan 1;499:110595
pubmed: 31563469
Clin Exp Metastasis. 2015 Jun;32(5):441-55
pubmed: 25895698
Nat Rev Cancer. 2011 Feb;11(2):85-95
pubmed: 21258394
Oncogene. 2010 May 20;29(20):2962-72
pubmed: 20228846
Cell Death Differ. 2016 Jun;23(6):962-78
pubmed: 26915293
World J Urol. 2013 Oct;31(5):1191-6
pubmed: 22544372
Cancer Res. 2000 Mar 1;60(5):1183-5
pubmed: 10728670
Bioorg Med Chem. 2017 Feb 1;25(3):977-999
pubmed: 28034647